FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare
Syndicate content

Amgen related Press Releases

Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452

Posted May 26, 2009

Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452Cytokinetics Receives Exercise Fee of $50 Million; Cytokinetics to Host a

... Read more...

Amgen Highlights Data to Be Presented at ASCO

Posted May 15, 2009

Amgen Highlights Data to Be Presented at ASCO THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 16, 2008 - Amgen (NASDAQ:AMGN) today announced it will present new data from the Company's oncology portfolio... Read more...

Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign

Posted April 30, 2009

Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign 'Coping with Cancer from the Outside In' Program to Launch at the Annual Oncology Nursing Society Congress THOUSAND OAKS,

... Read more...

FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab

Posted February 18, 2009

FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab THOUSAND OAKS, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Amgen Inc. (NASDAQ:AMGN) today announced that the U.S.

... Read more...

Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share

Posted January 26, 2009

Name: 
PR Newswire
Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Full Year 2008 Revenue Increased 2 Percent to $15.0 Billion; Fourth... Read more...

Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer

Posted November 20, 2008

Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer THOUSAND OAKS, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and

... Read more...

Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer

Posted November 19, 2008

Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer THOUSAND OAKS, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and... Read more...

Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe

Posted November 10, 2008

Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe Hands-On Science Research Program Expansion Brings the Amgen Foundation's Total Commitment to Amgen Scholars to

... Read more...

Amgen Positioned to Deliver Attractive Growth Over Next Five Years

Posted November 10, 2008

Amgen Positioned to Deliver Attractive Growth Over Next Five Years NEW YORK, November 07, 2008 /PRNewswire-FirstCall/ -- At an Amgen meeting of about 200 securities analysts and investors in New York

... Read more...

Amgen's Third Quarter 2008 Adjusted Earnings, Third Quarter 2008 Revenue Increase

Posted October 23, 2008

Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 Third Quarter 2008 Revenue Increased 7 Percent to $3.9 Billion Third Quarter 2008 GAAP Earnings Per Share were... Read more...